This is a demo store. No orders will be fulfilled.

10% 10ml CBD FULL “Queen Victoria” Cannabis, Oil

Delivery Time
ready for dispatch in 2-3 Days

INGREDIENTS:
Hemp (Cannabis sativa L), vegetable oil. Made by hand according to a traditional recipe with a full spectrum of ingredients.

was €22.00 Special Price €19.80
Incl. 10% VAT
In stock
SKU
CBDFULL-10-10-H-O

10% 10ml CBD FULL

“Queen Victoria” Cannabis extract (according to Paracelsus) in olive oil.

APPLICATION:
Shake well before use. Let 3 drops dissolve in the mouth 2-3 times a day and drink 0.2 l of water afterwards. Duration as required. The specified recommended daily dose should not be exceeded. A dietary supplement is not a substitute for a varied diet. Keep away from children. Store dark at room temperature.

More Information
Manufacturer Organic Gardens GmbH
Write Your Own Review
You're reviewing:10% 10ml CBD FULL “Queen Victoria” Cannabis, Oil

Hemp (Cannabis sativa L.)

Medicinal Plant of the Year 2018

The endocannabinoid system

is an important part of the central and peripheral nervous system responsible for signal transmission between the brain, spinal cord, vegetative nervous system and organs as well as a regulator of optimal physiological and cognitive processes such as: immune system,[1] vegetative nervous system,[2] social behavior and fear,[3] movement, memory, learning processes,[4] control over the formation, survival or death of neural and non-neural cells,[5] as well as for appetite,[6] pain, inflammation,[7] fat and energy metabolism[8] and much more.
   Changes in the endocannabinoid system or cannabinoid deficiency lead to a poorly functioning immune system and a variety of disease states.

Cannabis in the ancient art of healing 

The Use of hemp for a wide range of diseases has been documented for more than 4,800 years.

The Chinese used it for anesthesia during surgical procedures, for malaria, rheumatism, constipation, disorders of the female reproductive system and as a laxative.[9]

In India, hemp was used as an analgesic (toothache, headache and neuralgia), for cramps (tetanus, rabies, colic, diarrhea and epilepsy), for calming (mania, hysteria and anxiety), and for pain relief in inflammatory diseases such as rheumatism, as an antibiotic , used for asthma, bronchitis and many others.[10] [11] [12]

Egyptians used hemp to heal glaucoma,[13] gynecological diseases, pain,[14] fever, obstetrics,[15] parasites,[16] tumors, wounds, swellings, abscesses fever,[17] eyes, cancer and anorectal diseases.[18]

In the west, hemp as a medicine did not trigger a boom until the 19th century.

Hundreds of scientific articles on the healing powers of hemp have been published.[19] A wide range of diseases have been treated. By 1930, more than 2000 hemp-based drugs had been offered.[20] Numerous medical uses of hemp are described in "Sajous's Analytic Cyclopedia of Practical Medicine (1924)"[21] summarized.
After a global ban at the “Geneva Opium Conference 1925” and a demonization campaign, cannabis has disappeared as a medicine.

The Rediscovery

Under public pressure due to the diseases that conventional medicine is at a loss, scientists in the 1970s scrutinized the therapeutic value of cannabis. Over 100,000 studies and specialist articles on cannabis and cannabinoids have now been published. In Germany, treatment with drugs based on cannabis is permitted for over 60 diseases subject to prescription.[22]

According to studies, cannabinoids could represent a safe, inexpensive therapy for a wide range of disease states due to their natural origin and their low side effect profile and protective function against pathological conditions.

Cannabinoids and Pain 

Taking cannabinoids eliminates endocannabinoid deficiency as the main cause of migraines, fibromyalgia[23], irritable bowel syndrome,[24] and other treatment-resistant chronic pain.[25]  Cannabinoids affect the caudal vent, a part of the diencephalon that is responsible for the sense of pain, and are 10 times more effective than morphine by reducing the sensation of pain.[26] The endocannabinoid system influences pain control and mediates central stress-induced analgesia (insensitivity to pain).[27] Cannabinoid agonists suppress chronic and neuropathic pain by activating the CB1 and CB2 receptors in the spinal cord.[28] Cannabinoids reduce hyperalgesia (increased sensation of pain stimulus) by inhibiting the calcitonin gene-related peptide.[29] Cannabinoids inhibit glutamate release and reduce neuropathic pain and secondary and tertiary hyperalgesia (increased sensation of pain stimulus) in migraines and fibromyalgia.[30] Cannabinoids stimulate the production of beta-endorphin, an endogenous morphine with analgesic effects,[31] cannabinoids have twenty times the anti-inflammatory effect of aspirin and double the effect of hydrocortisone.[32] Cannabinoid-2 receptor agonist relieves pain and bone loss caused by bone cancer.[33] [34] Cannabinoids reduce hypersensitivity to pain caused by cancer and reduce inflammatory muscle pain.[35]

Cannabinoids and cancer

The most important property of cannabinoids in cancer treatment is the ability to kill tumor cells in a targeted manner.[36] Studies suggest that cannabinoids can be used in lung cancer,[37] Brain tumors,[38] [39] [40] [41] Breast cancer,[42] [43] [44] Pancreatic cancer,[45] [46] [47] Lymphoma, [48] [49] [50] Thyroid cancer, [51] [52] Skin cancer, [53] [54] Uterine carcinoma, [55] prostate carcinoma, [56] [57] [58] Colon cancer,[59] [60] [61] and bone cancer. [62] [63] Cannabinoids have similar or better effectiveness in relieving chemotherapy-induced nausea and vomiting than approved anti-emetic drugs.[64]

Cannabinoids in injuries and chronic neurodegenerative diseases

Cannabinoids are used because of the reduction of classic neurotoxic events, the removal of pathological deposits through improved neurological performance, reduced edema, infarct size, glioses, inflammation, blood-brain barrier disorders, in the treatment of brain injuries,[65] strokes[66] [67] [68] and chronic neurodegenerative diseases such as: Alzheimer,[69] [70] [71] [72]  Parkinson's,[73] [74] Amyotrophic Lateral Sclerosis,[75] [76] [77] Multiple sclerosis,[78] very promising.

Cannabinoids for psychosis, depression and anxiety

Cannabinoids reduce: acute stress,[79] [80] Panic attacks and phobic fears,[81] depression,[82] [83] [84] stress-related damage to the hippocampus,[85] psychosis, [86] and schizophrenia.[87] [88]

Neuroprotective and neuroregenerative properties of cannabinoids

Cannabinoids promote neuroplasticity (ability of the brain to change and adapt to experiences in response), [89] repair and regrowth,[90] [91]

also protect the nerve cells from dying. [92] [93] In this way they form a protection against neurodegenerative diseases such as post-traumatic stress disorder (PTSD), mood disorders, Alzheimer's, Huntington's, Parkinson's and schizophrenia. [94]

Cannabinoids and epilepsy

Patients with drug-resistant epilepsy have fewer seizures, [95] degeneration and neuron loss in the hippocampus,[96] especially in Lennox-Gastaut and Dravet syndrome.[97] [98] [99] [100] Patients have few or no seizures and better mood, communication, motor skills, language, behavior, Alertness and sleep[101] [102] Hemp extracts with high levels of CBD and low levels of THC have better anti-epileptic effects than approved drugs such as diphenylhydantoin and mysoline[103].

Cannabinoids inhibit opiate addiction and withdrawal symptoms

Cannabidiol inhibits narcotics addiction, withdrawal symptoms, heroin addiction, [104] [105] [106] Cocaine addiction[107] morphine addiction[108] [109] [110]  and tobacco addiction. [111]


[1] Pandey R., Mousawy K., Nagarkatti M., Nagarkatti P. (August 2009). "Endocannabinoids and Immune Regulation". Pharmacological Research. 60 (2): 85-92. doi: 10.1016 / j.phrs.2009.03.019
[Science Direct]

[2] Elphick MR, Egertová M (March 2001). "The neurobiology and evolution of cannabinoid signaling". Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 356 (1407):
[Pub Med]

[3] Häring M, Kaiser N, Monory K, Lutz B (2011). Burgess HA (ed.). "Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration". PLOS ONE. 6 (11): e26617. Bibcode: 2011PLoSO ... 626617H. doi: 10.1371 / journal.pone.0026617.
[PMC]

[4] Goodman J, Packard MG. The influence of cannabinoids on learning and memory processes of the dorsal striatum. Neurobiol Learn Mem. 2015; 125: 1-14. doi: 10.1016 / j.nlm.2015.06.008
[Pub Med]

[5]Cannabinoids and cell fate Manuel Guzmán CristinaSánchez Ismae Galve-Roperh Pharmacology & Therapeutics Volume 95, Issue 2, August 2002, Pages 175-184
[Science Direct]

[6] Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008; 19: 344-348.
[Pub Med]

[7]Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009; 11: 109-119.
[Pub Med]

[8] Ruminska A, Dobrzyn A. [The endocannabinoid system and its role in regulation of metabolism in peripheral tissues] Postepy Biochem. 2012; 58 (2): 127-134.
[Pub Med]

[9] Merlin MD. Archaeological evidence for the tradition of psychoactive plant use in the old world. Econ Bot 2003; 57: 295-323
[University of Hawai‘i at Manoa]

[10] Touwn M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981; 13 (1): 23-34.
[Taylor & Francis Group]

[11] Mikuriya TH. Marijuana in medicine: past, present and future. Calif Med. 1969; 110 (1): 34-40.
[PMC free article]

[12] Ethan Budd Russo CReDO Science Cannabis in India: Ancient lore and modern medicine
[ResearchGate free article]

[13] “Papyrus Ramesseum III”.
[Science in Ancient Egypt]

[14] “Papyrus Ebers”
[medizinische-papyri]

[15] “Berliner Papyrus”
[medizinische-papyri]

[16] “Papyrus Hearst”
[medizinische-papyri]

[17] Medical Book from Crocodilopolis P. Vindob. D. 6257
[Brigham Young University]

[18] Papyrus Chester Beatty IV
[British Museum]

[19] Grinspoon L. marijuana reconsidered. Cambridge, MA: Harvard University Press; 1971.

[21] "Sajous's analytic cyclopedia of practical medicine" Charles E de M Sajous; Louis T de M Sajous Philadelphia, FA Davis Company, 1924

[22] The State of Medical Care with Cannabis and Cannabinoids in Germany Dr. Franjo Grotenhermen “accept eV Federal Association for Accepting Drug Work and Humane Drug Policy” D-12161 Berlin
[akzept]

[23] Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief Schley M., Legler A., ??Skopp G., Schmelz M., Konrad C., Rukwied R. Curr Med Res Opin. 2006 Jul; 22 (7): 1269- 76.
[PubMed]

[24] Review Endocannabinoids and the gastrointestinal tract. Massa F, Monory KJ Endocrinol Invest. 2006; 29 (3 Suppl): 47-57.
[PubMed]

[25] Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2004 Feb-Apr; 25 (1-2): 31-9. PMID: 15159679.
[Pub Med]

[26] Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. Martin WJ, Hohmann AG, Walker JM J Neurosci. 1996 Oct 15; 16 (20): 6601-11.
[Pub Med]

[27] An endocannabinoid mechanism for stress-induced analgesia. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D Nature. 2005 Jun 23; 435 (7045): 1108-12.
[Pub Med]

[28] Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Rahn EJ, Makriyannis A, Hohmann AG Br J Pharmacol. 2007 Nov; 152 (5): 765-77.
[Pub Med]

[29] Antihyperalgesic effects of spinal cannabinoids. Richardson JD, Aanonsen L, Hargreaves KM Eur J Pharmacol. 1998 Mar 19; 345 (2): 145-53.
[Pub Med]

[30] Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Shen M, Piser ™, Seybold VS, Thayer SA J Neurosci. 1996 Jul 15; 16 (14): 4322-34.
[PubMed]

[31] Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA Brain Res Mol Brain Res. 1998 Mar 30; 55 (1): 126-32.
[Pub Med]

[32] Review Cannabinoids: the separation of central from peripheral effects on a structural basis. Evans FJ Planta Med. 1991 Oct; 57 (7): S60-7.
[Pub Med]

[33] Jia Sun, Ya-Qun Zhou, Shu-Ping Chen, Xiao-mei Wang, Bing-Yang Xu, Dan-Yang Li, Yu-Ke Tian, ??Da-Wei Ye, The endocannabinoid system: Novel targets for treating cancer induced bone pain , Biomedicine & Pharmacotherapy, Volume 120, 2019, 109504,
[Science Direct]

[34] AN Lozano-Ondoua, C. Wright, A. Vardanyan, T. King, TM Largent-Milnes, M. Nelson, JM Jimenez-Andrade, PW Mantyh, TW Vanderah A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss Life Sci. , 86 (17-18) (2010), pp.646-653
[Science Direct]

[35] Lois J Kehl, Darryl T Hamamoto, Paul W Wacnik, Devin L Croft, Blake D Norsted, George L Wilcox, Donald A Simone, A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain
[Science Direct]

[36] Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget. 2014; 5 (15): 5852-5872. doi: 10.18632 / oncotarget.2233
[PMC]

[37] Ravi J, Sneh A, Shilo K, Nasser MW, Ganju RK. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF / EGFR pathway. Oncotarget. 2014; 5 (9): 2475-2486.
[PMC]

[38] Blazquez C, Casanova ML, Planas A, Gomez Del Pulgar T, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M. Inhibition of tumor angiogenesis by cannabinoids. Faseb J. 2003; 17 (3): 529-531.
[Pub Med]

[39] Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V, Malicet C, Villuendas R, Gironella M, Gonzalez-Feria L, Piris MA, Iovanna JL, Guzman M, Velasco G. The stress -regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006; 9 (4): 301-312.
[Pub Med]

[40] Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, Haro A, Velasco G, Guzman M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 2008; 68 (6): 1945-1952.
[Pub Med]

[41] Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 2013; 34 (1): 48-57.
[Pub Med]

[42] Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One. 2011; 6 (9): e23901.
[PMC]

[43] Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011; 11 (9): 597-606.
[Pub Med]

[44] Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006; 66 (13): 6615-6621.
[Pub Med]

[45] Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Muller MW, Giese NA, Friess H, Kleeff J. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 2008; 122 (4): 742-750.
[PMC]

[46] Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G, Iovanna JL. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006; 66 (13): 6748-6755.
[Pub Med]

[47] Fogli S, Nieri P, Chicca A, Adinolfi B, Mariotti V, Iacopetti P, Breschi MC, Pellegrini S. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 2006; 580 (7): 1733-1739.
[Pub Med]

[48] Flygare J, Gustafsson K, Kimby E, Christensson B, Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett. 2005; 579 (30): 6885-6889.
[Pub Med]

[49] Liu WM, Scott KA, Shamash J, Joel S, Powles TB. Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk lymphoma. 2008; 49 (9): 1800-1809.
[Pub Med]

[50] Gustafsson K, Christensson B, Sander B, Flygare J. Cannabinoid receptor-mediated apoptosis induced by R (+) - methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mole pharmacol. 2006; 70 (5): 1612-1620.
[Pub Med]

[51] Shi Y, Zou M, Baitei EY, Alzahrani AS, Parhar RS, Al-Makhalafi Z, Al-Mohanna FA. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther. 2008; 15 (2): 101-107.
[Pub Med]

[52] Cozzolino R, Cali G, Bifulco M, Laccetti P. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. Invest New Drugs. 2010; 28 (2): 115-123.
[PubMed]

[53] Blazquez C, Carracedo A, Barrado L, Real PJ, Fernandez-Luna JL, Velasco G, Malum bres M, Guzman M. Cannabinoid receptors as novel targets for the treatment of melanoma. Faseb J. 2006; 20 (14): 2633-2635.
[Pub Med]

[54] Differential role of cannabinoids in the pathogenesis of skin cancer Nicole Glodde, Mira Jakobs, Tobias Bald, Thomas Tüting, Evelyn Gaffal, Laboratory of Experimental Dermatology, Dept. of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany Life Sciences Volume 138, October 1, 2015, Pages 35-40
[Science Direct]

[55] Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1 Gynecologic Oncology Volume 93, Issue 1, April 2004, Pages 182-188 Emmanuel Contassot, Mirna Tenan, Valérie Schnüriger, Marie-Françoise Pelte, Pierre-Yves Dietrich
[Science Direct]

[56] Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000; 141 (1): 118-126.
[Pub Med]

[57] Nithipatikoma K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004; 64 (24): 8826-8830.
[Pub Med]

[58] Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005; 65 (5): 1635-1641.
[Pub Med]

[59] Sreevalsan S, Joseph S, Jutooru I, Chadalapaka G, Safe SH. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res. 31 (11): 3799-3807.
[PMC]

[60] Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor a – Mediated Ceramide De novo Synthesis in Colon Cancer Cells DOI: 10.1158 / 1078-0432.CCR-08-0799 Published December 2008 Fabio Cianchi, Laura Papucci, Nicola Schiavone, Matteo Lulli, Lucia Magnelli , Maria Cristina Vinci, Luca Messerini, Clementina Manera, Elisa Ronconi, Paola Romagnani, Martino Donnini, Giuliano Perigli, Giacomo Trallori, Elisabetta Tanganelli, Sergio Capaccioli and Emanuela Masini
[Clinical Cancer Research]

[61] The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells July 1, 2010
[International Journal of Oncology]

[62] Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes ™, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci. 2010; 86 (17-18): 646-653.
[PMC]

[63] Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. Peripheral cannabinoid receptor, CB2, regulates bone mass . Proceedings of the National Academy of Sciences of the United States of America. 2006; 103 (3): 696-701.
[PMC]

[64] Melissa E. Badowski A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics Cancer Chemotherapy and Pharmacology volume 80, pages 441–449 (2017)
[springer]

[65] England TJ, Hind WH, Rasid NA, O'Sullivan SE. Cannabinoids in experimental stroke: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2015; 35: 348-358.
[Pub Med]

[66] Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 2003; 34: 2000-2006.
[Pub Med]

[67] Hayakawa K, Mishima K, Irie K, et al. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008; 55: 1280-1286.
[Pub Med]

[68] Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-2995.
[Pub Med]

[69] Fernández-Ruiz, J., Moro, MA & Martínez-Orgado, J. Cannabinoids in Neurodegenerative Disorders and Stroke / Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics 12, 793-806 (2015).
[Springer]

[70] Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-1913. Return to ref 87 in article
[PubMed]

[71] Aso E, Juvés S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AßPP / PS1 mice. J Alzheimer Dis 2013; 35: 847-858.
[IOS]

[72] Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994; 63: 637-652.
[Pub Med]

[73] Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, et al. Cannabidiol for the treatment of psychosis in Parkinsons disease J Psychopharmacol. (2009) 23: 979-83. doi: 10.1177 / 0269881108096519
[CrossRef]

[74] Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, et al. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Rev Bras Psiquiatr. (2013) 35: 380-6. doi: 10.1590 / 1516-4446-2012-0886
[CrossRef]

[75] Carter GT, Abood ME, Aggarwal SK, Dr. White. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trialsAm J Hosp Palliat Care 2010; 27: 347- 356. Return to ref 152 in article
[Pub Med]

[76] Rossi S, Bernardi G, Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 2010; 224: 92-102.
[Pub Med]

[77] Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7 immunoreactivities are increased in activated microglial cells / macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006; 6:12.
[Pub Med]

[78] Croxford JL, Miller SD. Towards cannabis and cannabinoid treatment of multiple sclerosis. Drugs Today (Barc). 2004; 40 (8): 663-676. doi: 10.1358 / dot.2004.40.8.850469
[Pub Med]

[79] Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioral and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. (2009) 156: 181-8. doi: 10.1111 / j.1476-5381.2008.00046.x
[CrossRef]

[80] Granjeiro EM, Gomes FV, ??Guimarães FS, Corrêa FM, Resstel LB. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav. (2011) 99: 743-8. doi: 10.1016 / j.pbb.2011.06.027
[Science Direct]

[81] Campos AC, Ferreira FR, Guimarães FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res. (2012) 46: 1501-10. doi: 10.1016 / j.jpsychires.2012.08.012
[CrossRef]

[82] Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. (2010) 159: 122-8. doi: 10.1111 / j.1476-5381.2009.00521.x
[CrossRef]

[83] Sartim AG, Guimarães FS, Joca SR. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res. (2016) 303: 218-27. doi: 10.1016 / j.bbr.2016.01.033
[CrossRef]

[84] Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, et al. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology (2016) 73: 123-9. doi: 10.1159 / 000443890
[CrossRef]

[85] Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Díaz-Alonso J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol. (2013) 16: 1407-19. doi: 10.1017 / S1461145712001502
[CrossRef]

[86] Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (1991) 104: 260-4. doi: 10.1007 / BF02244189
[CrossRef]

[87] Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 2: e94. doi: 10.1038 / tp.2012.15
[CrossRef]

[88] Hallak JE, Dursun SM, Bosi DC, de Macedo LR, Machado-de-Sousa JP, Abrão J, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35: 198-202. doi: 10.1016 / j.pnpbp.2010.11.002
[CrossRef]

[89] Campos, Alline C. and Fogaça, Manoela V. and Scarante, Franciele F. and Joca, Sâmia RL and Sales, Amanda J. and Gomes, Felipe V. and Sonego, Andreza B. and Rodrigues, Naielly S. and Galve-Roperh , Ismael and Guimarães, Francisco S. Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders “Frontiers in Pharmacology” DOI: 10.3389 / fphar.2017.00269
[CrossRef]

[90] Fuchs, E. and Flugge, G. (2014). Adult Neuroplasticity: More Than 40 Years of Research
[CrossRef]

[91] Wolf SA, et al. 2010 Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun. Signal. 810.1186 / 1478-811X-8-12 (doi: 10.1186 / 1478-811X-8-12).
[Pub Med]

[92] Wolf SA, Bick-Sander A, Fabel K, et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal. 2010; 8:12. Published 2010 Jun 17. doi: 10.1186 / 1478-811X-8-12
[Pub Med]

[93] Jia J, Le W. Molecular network of neuronal autophagy in the pathophysiology and treatment of depression. Neurosci Bull. (2015) 31: 427-34. doi: 10.1007 / s12264-015-1548-2
[CrossRef]

[94] Campos Alline C., Fogaça Manoela V., Scarante Franciele F., Joca Sâmia RL, Sales Amanda J., Gomes Felipe V., Sonego Andreza B., Rodrigues Naielly S., Galve-Roperh Ismael, Guimarães Francisco S.  Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders Frontiers in Pharmacology VOLUME = 8
[CrossRef]

[95] Trembly, B., and Sherman, M. (1990). “Double-blind clinical study of cannabidiol as a secondary anticonvulsant,” in Proceedings of the Marijuana 90 International Conference on Cannabis and Cannabinoids, Kolympari, Crete, July 1990 (Cologne: International Association for Cannabinoid Medicines).
[karger]

[96] Do Val-da Silva Raquel A., Peixoto-Santos Jose E., Kandratavicius Ludmyla, De Ross Jana B., Esteves Ingrid, De Martinis Bruno S., Alves Marcela NR, Scandiuzzi Renata C., Hallak Jaime EC, Zuardi Antonio W ., Crippa Jose A., Leite Joao P. Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy Frontiers in Pharmacology
[CrossRef]

[97] Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. (2016) 15: 270-8. doi: 10.1016 / S1474-4422 (15) 00379-8
[CrossRef]

[98] Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. (2017) 376: 2011-20. doi: 10.1056 / NEJMoa1611618
[CrossRef]

[99] Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. (2018) 378: 1888-97. doi: 10.1056 / NEJMoa1714631
[CrossRef]

[100] Cunha, JM, Carlini, EA, Pereira, AE, Ramos, OL, Pimentel, C., Gagliardi, R., et al. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21, 175-185. doi: 10.1159 / 000137430
[CrossRef]

[101] Brenda E. PorterCatherineJacobson Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy Epilepsy & Behavior
[CrossRef]

[102] CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience Michal Tzadok, Shimrit Uliel-Siboni, Ilan Linder, Uri Kramer, Orna Epstein, Shay Menascu, Andrea Nissenkorn, Omer Bar Yosef, Eli Hyman, Dorit Granot, Michael Dor, Tali Lerman Sagie, Bruria Ben-Zeev Seizure February 2016
[CrossRef]

[103] Izquierdo, I., Orsingher, OA & Berardi, AC Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia 28: 95-102 (1973).
[CrossRef]

[104] Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances
Yanhua Ren, John Whittard, Alejandro Higuera-Matas, Claudia V. Morris and Yasmin L. Hurd Journal of Neuroscience November 25, 2009, 29
[CrossRef]

[105] De Vries, TJ, Homberg, JR, Binnekade, R. et al. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168: 164-169 (2003).
[CrossRef]

[106] JL Scavone, RC Sterling, EJ Van Bockstaele Neuroscience. 2013 Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal
[PMC]

[107] Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release Pedro H. Gobira, Luciano R. Vilela, Bruno DC Gonçalves, Rebeca PM Santos, Antonio C. de Oliveira, Luciene B. Vieira, Daniele C. Aguiar, José A. Crippa, Fabricio A. Moreira NeuroToxicology August 15, 2015.
[CrossRef]

[108] Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder:
[Pub Med]

[109] Cannabinoid CB 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse Gregorio Cossu; Liana Fattore; Walter Fratta; Catherine Ledent; Marc Parmentier; Assunta Imperato; Georg A. Böhme Behav Brain Res. 2001
[Pub Med]

[110] Navarro M, Chowen J, Rocio A Carrera M, et al. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.
[Pub Med]

[111] Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013 Sep;38(9):2433-6. doi: 10.1016/j.addbeh.2013.03.011. Epub 2013 Apr 1. PMID: 23685330.
[ncbi]